• OPEN AN ACCOUNT
Indian Indices
Nifty
25,003.05 252.15
(1.02%)
Sensex
82,188.99 746.95
( 0.92%)
Bank Nifty
56,578.40 817.55
( 1.47%)
Nifty IT
37,294.85 186.90
( 0.50%)
Global Indices
Nasdaq
42,322.33 -126.41
(-0.30%)
Dow Jones
5,957.59 -34.22
(-0.57%)
Hang Seng
37,687.53 133.04
(0.35%)
Nikkei 225
8,837.91 26.87
(0.30%)
Forex
USD-INR
85.85 0.27
(0.32%)
EUR-INR
97.86 0.31
(0.32%)
GBP-INR
116.24 0.53
(0.46%)
JPY-INR
0.60 0.00
(0.24%)

EQUITY - MARKET SCREENER

Neuland Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
524558
INE794A01010
1182.3025039
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NEULANDLAB
82.79
16726.65
EPS(TTM)
Face Value()
Div & Yield %
157.47
10
0.09
 

UPL announces revision in credit rating outlook of UPL Corp
Jun 04,2025

UPL announced that Fitch Ratings vide its publication dated 04 June 2025, has communicated revision in the credit rating outlook of UPL Corporation (UPL Corp), wholly owned subsidiary of UPL.

Fitch has revised its Long-Term Issuer Default Rating (IDR) outlook on UPL Corp from “Negative” to “Stable”. Fitch affirmed the IDR at 'BB' of UPL Corp. Fitch also affirmed the senior unsecured rating and the ratings of its senior unsecured notes at 'BB'.